Trials / Completed
CompletedNCT05174065
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2022-03-08
- Primary completion
- 2023-08-19
- Completion
- 2024-06-01
- First posted
- 2021-12-30
- Last updated
- 2025-04-09
- Results posted
- 2025-04-09
Locations
40 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05174065. Inclusion in this directory is not an endorsement.